Existing and Emerging Shorter-Acting Nondaily Hormonal Contraceptives
This supplement is sponsored byAgile Therapeutics®.
March 1, 2013|ObGyn
Author and Disclosure Information
Andrew M. Kaunitz, MD; Anita Nelson, MD; and Sujatha Prabhakaran, MD, MPH
Dr. Kaunitz reports that his institution receives research funding from Agile, Bayer, and Teva, and that he is a consultant for Agile, Bayer, and Merck. Dr. Nelson reports receiving grants/research funding from Bayer, Merck, Pfizer, and Teva; receiving speakers bureau honoraria from Bayer, Merck. and Teva; and being a consultant/advisory board member for Agile, Bayer, Ferring, Merck, Teva, and Watson. Dr. Prabhakaran reports that she has no financial relationships to disclose.
Over half of all pregnancies in the United States (US) are unintended; an estimated 42% of these unintended pregnancies result in induced abortion or miscarriage.1-3 Unintended pregnancies have profound adverse effects not only on maternal health, but also on infant and child health outcomes, including increased risk of low birth-weight, neonatal mortality, and infant developmental delay.4 To decrease unintended pregnancy, clinicians must collaborate with their patients to optimize correct and consistent contraceptive use.
